Hereditary hypo/de-pigmented dermatoses: An overview

Sehgal, Virendra; Srivastava, Govind

doi:10.1111/j.1365-4632.2006.03105.x

Cited by 3 publications

(4 citation statements)

References 116 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A previous histopathological study showed that both the amount of melanin and the number of melanocytes were decreased in patients with ND 11 . Electron micro‐scopic finding indicated the reduction of melanosomes inside the melanocytes and type of melanosomes was abnormal 12 .…”

Section: Discussionmentioning

confidence: 90%

“…A previous histopathological study showed that both the amount of melanin and the number of melanocytes were decreased in patients with ND. 11 Electron microscopic finding indicated the reduction of melanosomes inside the melanocytes and type of melanosomes was abnormal. 12 We found the RCM features of ND include the small and low brightness pigment cells and low density of the pigment cells, which agree with the previous studies.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

In vivo reflectance confocal microscopy for the differential diagnosis between vitiligo and nevus depigmentosus

Pan

Zhang

et al. 2011

Int J Dermatology

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 90%

Section: Discussionmentioning

confidence: 99%

In vivo reflectance confocal microscopy for the differential diagnosis between vitiligo and nevus depigmentosus

Pan

Zhang

et al. 2011

Int J Dermatology

View full text Add to dashboard Cite

show abstract

“…18 However, a robust homology model built using structural data from TyB2 and Ipomea batatas catechol oxidase has recently been published. In humans, melanin-related disorders are known to cause cutaneous hyperpigmentation, 20 skin lesions, 21 or melanoma resistance to conventional therapies. 22 As Ty inhibition is a well-established strategy for controlling melanin production in vivo, as demonstrated again recently, 23 the development of TyH inhibitors raises considerable interest in dermocosmetics 24 and cancer therapies 25 fields.…”

mentioning

confidence: 99%

2-Hydroxypyridine-N-oxide-Embedded Aurones as Potent Human Tyrosinase Inhibitors

Haudecoeur

Carotti

Gouron

et al. 2016

ACS Med. Chem. Lett.

View full text Add to dashboard Cite

With the aim to develop effective and selective human tyrosinase inhibitors, we investigated aurone derivatives whose B-ring was replaced by a non-oxidizable 2-hydroxypyridine-N-oxide (HOPNO) moiety. These aurones were synthesized and evaluated as inhibitors of purified human tyrosinase. Excellent inhibition activity was revealed and rationalized by theoretical calculations. The aurone backbone was especially found to play a crucial role, as the HOPNO moiety alone provided very modest activity on human tyrosinase. Furthermore, the in vitro activity was confirmed by measuring the melanogenesis suppression ability of the compounds in melanoma cell lysates and whole cells. Our study reveals that HOPNO-embedded 6-hydroxyaurone is to date the most effective inhibitor of isolated human tyrosinase. Owing to its low toxicity and its high inhibition activity, it could represent a milestone on the path toward new valuable agents in dermocosmetics, as well as in medical fields where it was recently suggested that tyrosinase could play key roles.

show abstract

“…Information should be elicited from the patient on family history, onset, and development of pigmentation changes. Patients should also be asked about any related impact on overall health as well as any pathologies involving other organs [5, 6]. A medication history should also be taken and should include occupational contacts with solvents which can lead to hyperpigmentation or – as a result of toxic effects on melanocytes – hypopigmentation (Table 1).…”

Section: Diagnostic Proceduresmentioning

confidence: 99%

Disorders of Pigmentation

Fistarol

Itin

2010

J Deutsche Derma Gesell

103

View full text Add to dashboard Cite

Skin color is highly individual and the variations are controlled by numerous genes. The different skin colors result from the size and number of melanosomes and do not mirror the amount of melanocytes. Disorders of pigmentation can result from migration abnormalities of melanocytes from the neural crest to the skin during embryogenesis. In addition, impairment of melanosome transfer to the surrounding keratinocytes, an alteration in melanin synthesis and a defective degradation or removal of melanin may lead to abnormal skin pigmentation. Immunologic or toxic mediated destructions of melanocytes can end in pigmentation disorders. Disorders of pigmentation are classified in hypo- or hyperpigmentation which can occur as a genetic or acquired disease. They can manifest locally or diffuse. Congenital hypopigmentation can be restricted to the skin as in piebaldism or they represent a systemic disease as in Menkes disease or phenylketonuria. Localized hypo- or hyperpigmentation in children may serve as markers for systemic diseases. Ash-leaf hypopigmentation are characteristic for tuberous sclerosis and more than 5 café-au-lait spots suggest neurofibromatosis 1 (von Recklinghausen disease). The most common autoimmune-induced depigmentation is vitiligo. Generalized hyperpigmentation only rarely reflects a primary genetic disorder but is most often from acquired diseases as in Addison disease, secondary hemochromatosis or primary biliary cirrhosis. Treatment of pigmentation disorders are based on a diagnosis which sometimes allow a specific intervention. Cosmetically acceptable results are difficult to obtain.

show abstract

Hereditary hypo/de-pigmented dermatoses: An overview

Cited by 3 publications

References 116 publications

In vivo reflectance confocal microscopy for the differential diagnosis between vitiligo and nevus depigmentosus

In vivo reflectance confocal microscopy for the differential diagnosis between vitiligo and nevus depigmentosus

2-Hydroxypyridine-N-oxide-Embedded Aurones as Potent Human Tyrosinase Inhibitors

Disorders of Pigmentation

Contact Info

Product

Resources

About